Last Price
0.383
Today's Change
+0.015 (4.07%)
Day's Change
0.358 - 0.419
Trading Volume
5,698,693
Market Cap
23 Million
Shares Outstanding
60 Million
Avg Volume
2,907,447
Avg Price (50 Days)
4.49
Avg Price (200 Days)
4.20
PE Ratio
-0.33
EPS
-1.17
Earnings Announcement
06-Aug-2024
Previous Close
0.37
Open
0.37
Day's Range
0.3576 - 0.4185
Year Range
0.347 - 6.79
Trading Volume
5,714,668
1 Day Change
4.19%
5 Day Change
5.42%
1 Month Change
-92.62%
3 Month Change
-92.34%
6 Month Change
-86.88%
Ytd Change
-92.63%
1 Year Change
-85.76%
3 Year Change
-94.64%
5 Year Change
-97.94%
10 Year Change
-97.94%
Max Change
-97.94%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.